Brief: Bergenbio: Update From Ongoing Phase II Bemcentinib Combination Study In Refractory NSCLC At WCLC 2020

Oncoinvent ASA

29/01/2021 06:07

Jan 29 (Reuters) - Bergenbio ASA  BGBIO.OL :
    * BERGENBIO PRESENTS UPDATES FROM ONGOING PHASE II
BEMCENTINIB
COMBINATION STUDY IN REFRACTORY NSCLC AT WCLC 2020
    * PRESENTATION WILL PROVIDE UPDATED DATA FROM COHORT B OF
STUDY,
ASSESSING SAFETY AND EFFICACY OF BEMCENTINIB IN COMBINATION WITH
ANTI-PD-1 THERAPY PEMBROLIZUMAB, IN 16 REFRACTORY NSCLC PATIENTS
PREVIOUSLY TREATED WITH A PD-L1 OR PD-1 CHECKPOINT INHIBITOR
(CPI) AS A MONOTHERAPY
    * INTERIM DATA FROM COHORT B SHOWED THAT OVERALL RESPONSE
RATE
AMONG SEVEN EVALUABLE CAXL POSITIVE PATIENTS WAS 14% WITH A
DISEASE CONTROL RATE OF 86% AND A 2.5-FOLD IMPROVEMENT IN
PROGRESSION FREE SURVIVAL RATE IN CAXL POSITIVE PATIENTS
    * IN SEVEN CAXL NEGATIVE PATIENTS, ALL SHOWED CLINICAL
PROGRESSION
WITH 29% OF PATIENTS DEMONSTRATING CLINICAL BENEFIT FOLLOWING
TREATMENT
    * BERGENBIO ASA - INTERIM DATA SHOWS THAT BEMCENTINIB IN
COMBINATION WITH PEMBROLIZUMAB WAS WELL-TOLERATED AND SHOWS
PROMISING CLINICAL ACTIVITY IN REFRACTORY LUNG CANCER
    * WHOLE TUMOUR GENE EXPRESSION ANALYSIS IDENTIFIED AN AXL
POSITIVE
GENE SIGNATURE CHARACTERISTIC OF AN IMMUNE SUPPRESSION
MECHANISM, IN PATIENTS WITH ACQUIRED (COHORT B) RESISTANCE TO
CPIS.

Source text for Eikon:  ID:nWkr7HNjYx 
Further company coverage:  BGBIO.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))